Abliva to participate in World Mitochondrial Disease Week 2021

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in World Mitochondrial Disease Week through videos that will be released on Abliva’s website daily during the week, 19 – 25 September.

The videos will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases (PMDs). Over the week we will highlight the huge unmet medical need in the area and discuss Abliva’s own efforts to treat mitochondrial disease patients with our two clinical stage compounds.

Starting 19 September, Abliva’s videos will be posted daily on https://abliva.com/poster/presentationer/world-mitochondrial-disease-week-2021/ as well as on the company’s YouTube channel and LinkedIn page.

World Mitochondrial Disease Week is an initiative of International Mito Patients (IMP). The purpose of the World Mitochondrial Disease Week is to raise awareness of mitochondrial disease (mito) on a global scale through educational, fundraising and advocacy activities.
https://mitochondrialdiseaseweek.org

About primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the cells’ ability to convert energy. The disorders can manifest differently depending on the organs in which the genetic defects are present. They have historically been viewed as clinical syndromes and more recently as disease spectra, caused by genetic defects affecting mitochondrial function. An estimated 125 in every 1,000,000 people suffer from a primary mitochondrial disease. The diseases often present in early childhood and lead to severe symptoms such as mental retardation, fatigue, myopathy, heart failure and rhythm disturbances, diabetes, movement disorders, stroke-like episodes, and epileptic seizures.

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva to participate in World Mitochondrial Disease Week 2021